tbuckley/cabot-search huggingface dataset:
18F-FDG PET/CT in Bilateral Breasts Metastasis From Ovarian Carcinoma
Authors: Suman S. Karanth, Dharmender Malik, Gaurav Khanna, Ishita B. Sen, Divya Manda, Vinod Raina
Journal: Clinical Nuclear Medicine (2022)

Ovarian carcinomas generally metastasize within the peritoneal cavity due to exfoliation of malignant cells from primary tumor. Metastasis to the breasts is an unusual event and may mimic primary neoplastic disease. Usually, breast metastasis presents as a single isolated, well-circumscribed soft tissue lesion, and serous papillary carcinoma is the most common type of ovarian tumor that can metastasize to the breast. Concurrent bilateral breast metastasis is rare event. We present a follow-up case of metastatic carcinoma ovary, demonstrating FDG-avid soft tissue density masses in the bilateral breast parenchyma along with bilateral axillary lymphadenopathy, biopsy of which revealed metastatic deposits from carcinoma ovary.
Media Watch
Authors: Marilynn Larkin
Journal: The Lancet Infectious Diseases (2004)

A collaborative effort between chemists and engineers at the University of Buffalo (Buffalo, NY, USA) has yielded the BioBlower, a device that could swiftly destroy airborne pathogens in structures as large as the senate building in Washington, DC, which had to remain closed for several months after anthrax was detected there in 2001. The BioBlower has the potential to eradicate in minutes such pathogens as anthrax, smallpox, tuberculosis, and the severe acute respiratory syndrome coronavirus, according to its co-inventors.
SARS-CoV-2 treatment effects induced by ACE2-expressing microparticles are explained by the oxidized cholesterol-increased endosomal pH of alveolar macrophages
Authors: Zhenfeng Wang, Jiadi Lv, Pin Yu, Yajin Qu, Yabo Zhou, Li Zhou, Qiangqiang Zhu, Shunshun Li, Jiangping Song, Wei Deng, Ran Gao, Yuying Liu, Jiangning Liu, Wei-Min Tong, Chuan Qin, Bo Huang
Journal: Cellular and Molecular Immunology (2022)

Exploring the cross-talk between the immune system and advanced biomaterials to treat SARS-CoV-2 infection is a promising strategy. Here, we show that ACE2-overexpressing A549 cell-derived microparticles (AO-MPs) are a potential therapeutic agent against SARS-CoV-2 infection. Intranasally administered AO-MPs dexterously navigate the anatomical and biological features of the lungs to enter the alveoli and are taken up by alveolar macrophages (AMs). Then, AO-MPs increase the endosomal pH but decrease the lysosomal pH in AMs, thus escorting bound SARS-CoV-2 from phago-endosomes to lysosomes for degradation. This pH regulation is attributable to oxidized cholesterol, which is enriched in AO-MPs and translocated to endosomal membranes, thus interfering with proton pumps and impairing endosomal acidification. In addition to promoting viral degradation, AO-MPs also inhibit the proinflammatory phenotype of AMs, leading to increased treatment efficacy in a SARS-CoV-2-infected mouse model without side effects. These findings highlight the potential use of AO-MPs to treat SARS-CoV-2-infected patients and showcase the feasibility of MP therapies for combatting emerging respiratory viruses in the future.
Mammary Tumors in Mice Presumably Free of the Mammary-Tumor Agent
Journal: JNCI Journal of the National Cancer Institute (1948)

Mammary Tumors in Mice Presumably Free of the Mammary-Tumor Agent Howard B. Andervont, Howard B. Andervont Biologist Search for other works by this author on: Oxford Academic PubMed Google Scholar Thelma B. Dunn Thelma B. Dunn Pathologist National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 8, Issue 5-6, April-June, Pages 227, https://doi.org/10.1093/jnci/8.5-6.227 Published: 01 April 1948 Article history Published: 01 April 1948 Received: 14 April 1948
Outcomes of patients with hematologic malignancies and COVID-19 from the Hematologic Cancer Registry of India
Authors: Arihant Jain, Lingaraj Nayak, Uday Prakash Kulkarni, Nikita Mehra, Uday Yanamandra, Smita Kayal, Sharat Damodar, Joseph M. John, Prashant Mehta, Suvir Singh, Pritesh Munot, Sushil Selvarajan, Venkatraman Radhakrishnan, Deepesh Lad, Rajan Kapoor, Biswajit Dubashi, Ram S. Bharath, Hasmukh Jain, P. K. Jayachandran, Jeyaseelan Lakshmanan, Thenmozhi Mani, Jayashree Thorat, Satyaranjan Das, Omprakash Karunamurthy, Biju George, Manju Sengar, Pankaj Malhotra
Journal: Blood Cancer Journal (2022)

High flow nasal canula/ventilatory support 86/556 (15.5) 58/86 (67.4) 0/0 6/16 (37.5) 52/70 (74.3) a Cases were included for an outcome only if information of that outcome was reported.b Includes chronic lymphocytic leukemia.c Includes
Distinct properties of adipose stem cell subpopulations determine fat depot-specific characteristics
Authors: Hahn Nahmgoong, Yong Geun Jeon, Eun Seo Park, Yoon Ha Choi, Sang Mun Han, Jeu Park, Yul Ji, Jee Hyung Sohn, Ji Seul Han, Ye Young Kim, Injae Hwang, Yun Kyung Lee, Jin Young Huh, Sung Sik Choe, Tae Jung Oh, Sung Hee Choi, Jong Kyoung Kim, Jae Bum Kim
Journal: Cell Metabolism (2022)
Cardiac toxicities of fluoropyrimidine chemotherapy: A literature review and evaluation of current practice at a large U.K. cancer center.
Authors: Christopher Williams, Christopher Saunderson, Justin Liu, Noe Noe Aung, Caroline Cartlidge, Alice Dewdney, Richard Cubbon
Journal: Journal of Clinical Oncology (2022)

72 Background: Fluoropyrimidine chemotherapy is a mainstay of the adjuvant and palliative management of colorectal cancer. Cardiac toxicities—including angina, myocardial infarction and arrhythmias—are uncommon complications thought to be mediated by coronary vasospasm. Although potentially life-threatening, they remain poorly described and consensus guidelines regarding patient selection are lacking. To assess current understanding of this toxicity, we performed a literature review of the topic. We then evaluated fluoropyrimidine use at a large UK cancer center to investigate current practice. Methods: MEDLINE, EMBASE and the Cochrane central register of controlled trials were searched to March 1 2021 using the search terms (fluorouracil OR capecitabine) AND—separately—cardiotoxicity, heart disease, and rechallenge*. Original research articles in English were included and their findings summarised. The case notes of all patients who underwent surgery for pathological stage III colon cancer between January 1 2017 and December 31 2019 at Leeds Cancer Centre were reviewed. The proportion of patients who experienced cardiac toxicity during adjuvant chemotherapy was assessed. The proportion of patients who were not offered adjuvant chemotherapy due to cardiac risk was identified. Results: The three search strategies identified 582, 55 and 21 citations respectively, of which 28, 7 and 7 full texts were retrieved for further evaluation following review of titles and abstracts. The reported incidence of fluoropyrimidine cardiotoxicity varied widely, as did its definition. Over half of toxicity cases described were ischaemic. Reported risk factors included those for coronary artery disease, although this was not a consistent finding. 125 patients underwent surgery for stage III colon cancer in the study period of whom 81 (65%) received adjuvant chemotherapy. 2 (2.5%) patients failed to complete adjuvant treatment due to cardiac toxicity (angina; cardiac arrest). Pre-existing cardiovascular disease was cited as a reason for not offering adjuvant chemotherapy in 13 of 44 cases (30%). Conclusions: Review of the literature revealed a poor evidence base to guide treatment decisions regarding fluoropyrimidine chemotherapy and cardiac risk. Rates of cardiac toxicity at our center were within expected limits. A number of patients were denied adjuvant chemotherapy due to perceived cardiac risk. A clearer understanding of the pathophysiology and management of fluoropyrimidine cardiotoxicity is urgently required to avoid unnecessarily denying patients effective anti-cancer therapy.
Medicolegal
Journal: JAMA (1923)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Sonomicrometry myocardial tagging quantifies regional remodeling after anteroapical infarction Benjamin M. Jackson, Robert C. Gorman, Joseph H. Gorman, III, T. Sloane Guy, IV, Sina L. Moainie, Theodore Plappert, Martin St. John-Sutton, L. Henry Edmunds, Jr.. University of Pennsylvania School of Medicine, Philadelphia, PA
Journal: Journal of the American College of Cardiology (2001)
COVID-19 and thrombosis: a continuing story
Authors: None The Lancet Haematology
Journal: The Lancet Haematology (2021)

Celebrations to ring in 2021 were subdued in many parts of the world as traditional gatherings were cancelled to help stem the rising number of cases of COVID-19. The new, more transmissible, variants of the virus are causing pressure on health-care systems around the world and, although the positive results from numerous vaccine trials announced at the end of the year seemed to offer a glimmer of hope, it is clear now that there will be many more deaths before the disease is brought under control.
Oxidative stress and redox equilibrium in patients with coronary vasospasm Kunihisa Miwa, Toshinori Makita, Katuhisa Ishii, Nobuaki Okuda, Takaharu Saito, Chiharu Kishimoto, Hajime Nakamura, Junji Yodoi. Kansai Electric Power Hospital, Osaka, Japan, Kyoto University, Kyoto, Japan
Journal: Journal of the American College of Cardiology (2001)
The Cover
Authors: George E. Ehrlich
Journal: JAMA (1987)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Zd4522(Rosuvastatin) compared with diet and maximal lipid therapy in patients with heterozygous familial hypercholesterolemia Evan A. Stein, Glenn Lamkin, Peter M. Laskarzewski, Michael D. Cressman. Metabolic and Atherosclerosis Research Center, Cincinnati, OH, Medical Research Laboratories, Highland Heights, KY
Journal: Journal of the American College of Cardiology (2001)
Targeting RUNX1 as a novel treatment modality for pulmonary arterial hypertension
Authors: Euy-Myoung Jeong, Mandy Pereira, Eui-Young So, Keith Q Wu, Michael Del Tatto, Sicheng Wen, Mark S Dooner, Patrycja M Dubielecka, Anthony M Reginato, Corey E Ventetuolo, Peter J Quesenberry, James R Klinger, Olin D Liang
Journal: Cardiovascular Research (2022)

Abstract Aims Pulmonary arterial hypertension (PAH) is a fatal disease without a cure. Previously, we found that transcription factor RUNX1-dependent haematopoietic transformation of endothelial progenitor cells may contribute to the pathogenesis of PAH. However, the therapeutic potential of RUNX1 inhibition to reverse established PAH remains unknown. In the current study, we aimed to determine whether RUNX1 inhibition was sufficient to reverse Sugen/hypoxia (SuHx)-induced pulmonary hypertension (PH) in rats. We also aimed to demonstrate possible mechanisms involved. Methods and results We administered a small molecule specific RUNX1 inhibitor Ro5-3335 before, during, and after the development of SuHx-PH in rats to investigate its therapeutic potential. We quantified lung macrophage recruitment and activation in vivo and in vitro in the presence or absence of the RUNX1 inhibitor. We generated conditional VE-cadherin-CreERT2; ZsGreen mice for labelling adult endothelium and lineage tracing in the SuHx-PH model. We also generated conditional Cdh5-CreERT2; Runx1(flox/flox) mice to delete Runx1 gene in adult endothelium and LysM-Cre; Runx1(flox/flox) mice to delete Runx1 gene in cells of myeloid lineage, and then subjected these mice to SuHx-PH induction. RUNX1 inhibition in vivo effectively prevented the development, blocked the progression, and reversed established SuHx-induced PH in rats. RUNX1 inhibition significantly dampened lung macrophage recruitment and activation. Furthermore, lineage tracing with the inducible VE-cadherin-CreERT2; ZsGreen mice demonstrated that a RUNX1-dependent endothelial to haematopoietic transformation occurred during the development of SuHx-PH. Finally, tissue-specific deletion of Runx1 gene either in adult endothelium or in cells of myeloid lineage prevented the mice from developing SuHx-PH, suggesting that RUNX1 is required for the development of PH. Conclusion By blocking RUNX1-dependent endothelial to haematopoietic transformation and pulmonary macrophage recruitment and activation, targeting RUNX1 may be as a novel treatment modality for pulmonary arterial hypertension.
Safety and efficacy of vascular beta-radiation of in-stent-restenosis with a 188Re liquid-filled PTCA balloon system Klaus Reynen, Ulrich Koeckeritz, Johannes Kropp, Gerd Wunderlich, Alexander Schmeisser, Ruth H Strasser. Heart Center Dresden, Dresden, Germany, Technical University Dresden, Dresden, Germany
Journal: Journal of the American College of Cardiology (2001)
A cross-sectional study on effectiveness of antiemetic regimens for chemotherapy-induced nausea and vomiting: A single-center retrospect study of 1,000 patients.
Authors: Luo Cong, Mingge Shang, Lei Chen, Xu Qi, Li Jingjing, Qing Wei, Jieer Ying
Journal: Journal of Clinical Oncology (2021)

e24100 Background: Chemotherapy-induced nausea and vomiting (CINV) is a common symptom in patients who undergoing chemotherapy, it is very important to control CINV to maintain dose intensity and patients' quality of life. To analyse the current situation of CINV for the tumor patients who undergoing chemotherapy, we used a cross-sectional survey to assess CINV status in those patients, and whether the drugs used by doctors in each department met the guidelines, and compared the efficacy of different antiemetic regimens on acute and delayed CINV overall post-chemotherapy periods. Methods: 1,000 patients were randomly selected from 5,468 patients with chemotherapy discharged from different departments of Zhejiang cancer hospital in China between April 1 and April 30, 2019, and there were 87 responses totally. Medical records were collected on patient’s department (internal medicine, surgery, radiotherapy, interventional), chemotherapy regimens, anti-vomiting program, etc. Patients' feedbacks were recorded by CTCAE4.03 standard using MASCC antiemetic tool (Mat). Participants reported the frequency, severity, and impact on daily life of CINV from the day of chemotherapy administration up to 5 days thereafter and nausea and vomiting, as well as pharmacologic and chemotherapy used. Results: A total of 66 antineoplastic drugs were investigated, of which 52 were given intravenously and 14 orally.There were 9, 7, 50 drugs with high, moderate and low emetic risk respectively.The most prescribed prophylactic regimens for the management of CINV were aprepitant, 5-HT3R, H1-RA and dexamethasone and metoclopramide. The overall incidence of CINV were 44.34%, 24.57% and 39.66% patients reported nausea or vomiting in the acute and delayed phases. 19.89% patients had both acute and delayed CINV. The consistency rate of antiemetic with guideline was 63.19% in internal medicine department, 61.41% in surgery department and 52.91% in radiotherapy department, which showed a significant gap between the actual use of drugs and the recommended guidelines(P = 0.001). In 875 patients, 518 patients received guideline recommended antiemetic regimen, the CINV rates of complete response (CR), defined as no vomiting with no rescue medication, were 61.58%. While the CR rates in other 357 patients were 47.06%(P &lt; 0.001). Nausea was more frequent across the overall observation period (43.77% VS 18.86%). However, vomiting was more sever and had a greater impact on life than nausea. Conclusions: Overall, adherence to the guideline recommendations in different departments were poor with varying degrees. Future studies should set hard outcomes, such as the absence of any symptoms, as a primary end point. The standardized management of CINV in patients need to be further strengthened and doctors need to use drugs more regularly to reduce the occurrence of CINV in patients.
"PRIMARY" SYSTEMIC AMYLOIDOSIS AND MYELOMA
Journal: JAMA (1961)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Pulmonary Tuberculosis.
Journal: JAMA (1927)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Obstetric flying squads and mobile resuscitation units.
Authors: Andrew Johnson, Stephen Spiro, S Clarke
Journal: BMJ (1977)

reported a rise of 22 beats/min after a similar dose in acute asthma, while we have shown a rise of 28 beats/min one minute after salbuta- mol 200 xjg injected over a one-minute period to convalescent asthmatics.5 Indeed, Mr Neville and his colleagues reported a rise of 31 beats/min on completion of their intravenous injection.It would seem likely that had Professor Femi-Pearse measured the pulse rate sooner after completion of the bolus injection of salbutamol a greater tachycardia would have been apparent.In view of these other reports we feel that salbutamol should be administered intravenously slowly (over at least five minutes) and that, with time, cardiotoxic effects or deaths will be observed if this effective bronchodilator is given rapidly as suggested.